Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Trazodone Hydrochloride

FDA-approved product (tablet, oral), marketed as Desyrel, Oleptro, Raldesy and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Trazodone Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Depressive disorder
  • Major depressive disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antidepressants
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA42.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Trazodone Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Trazodone Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.

    NCT00775203 · start 2007-06

    Registered record
    Registry ID
    NCT00775203
    Conditions
    Major Depressive Disorder
    Interventions
    Trazodone Hydrochloride (HCl) Extended-Release Tablets; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-06
    Completion
    2007-11
    Enrolment
    412

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMajor Depressive Disorder
    InterventionTrazodone Hydrochloride (HCl) Extended-Release Tablets; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Patient-Centered Collaborative Care for Preventing Post-Traumatic Stress Disorder After Traumatic Injury

    NCT00270959 · start 2006-06

    Registered record
    Registry ID
    NCT00270959
    Conditions
    Post-Traumatic Stress Disorder
    Interventions
    Cognitive Behavioral Therapy; Motivational Interviewing; FDA-Approved Anti-Anxiety Medications; Standard Care Control
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-06
    Completion
    2013-03
    Enrolment
    207

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPost-Traumatic Stress Disorder
    InterventionCognitive Behavioral Therapy; Motivational Interviewing; FDA-Approved Anti-Anxiety Medications; Standard Care Control
    PhasePhase 1
    Registry statusCompleted

  • Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness

    NCT00817011 · start 2006-04

    Registered record
    Registry ID
    NCT00817011
    Conditions
    Depression; Antidepressant Drug Adverse Reaction
    Interventions
    SSRI treated group; non-SSRI treated group
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2006-04
    Completion
    2018-03
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression; Antidepressant Drug Adverse Reaction
    InterventionSSRI treated group; non-SSRI treated group
    PhaseNot applicable
    Registry statusUnknown

  • Comparative Bioavailability Study of Two Prototypes of Trazodone Controlled-release Products and Two Marketed Reference Products in Healthy Volunteers

    NCT01121913 · start 2005-03

    Registered record
    Registry ID
    NCT01121913
    Conditions
    Healthy
    Interventions
    Trazodone HCl; Trazodone HCl; Trazodone HCl; Trazodone HCl
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-03
    Completion
    Not recorded
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTrazodone HCl; Trazodone HCl; Trazodone HCl; Trazodone HCl
    PhasePhase 1
    Registry statusCompleted

  • Treatment of Neuroleptic Induced Acute Akathisia With Trazodone

    NCT00659919 · start 2000-11

    Registered record
    Registry ID
    NCT00659919
    Conditions
    Schizophrenia
    Interventions
    Placebo; Trazodone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2000-11
    Completion
    2003-12
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionPlacebo; Trazodone
    PhasePhase 4
    Registry statusCompleted